Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07502664 · ClinicalTrials.gov registry record
Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)
A clinical trial, sponsored by Ray Therapeutics.
- Recruiting
- Registry status
- 25
- Enrollment target
NCT07502664 is a clinical trial that is actively recruiting participants, run by Ray Therapeutics. The registered enrollment target is 25 participants.
The verdict
NCT07502664 is actively recruiting participants, sponsored by Ray Therapeutics.
- RECRUITING
- Registry status
- 25 participants
- Enrollment target
Study Summary
The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision. The mission of the VRAI is to enable the highest quality, standardized efficacy testing of patients with visual impairment. The VRAI facilitates the development and refinement of existing endpoints specifically for testing patients with Low Vision.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2026-02-19 |
| Est. Completion | 2027-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07502664
The ClinicalTrials.gov registry entry for NCT07502664 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ray Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT07502664 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07502664 about?
NCT07502664 is a clinical study titled "Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)". The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision. The mission of the VRAI is to enable the highest quality, standardized efficacy testing of patients with visual impairment. The...
What is the current status of trial NCT07502664?
This trial is currently recruiting. The enrollment target is 25 participants. The study started on 2026-02-19. Estimated completion is 2027-02.
Who is sponsoring clinical trial NCT07502664?
This trial is sponsored by Ray Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.